
GC Green Cross M&S announced on the 18th that it has obtained export approval from the Ministry of Food and Drug Safety for its hantavirus rapid and molecular diagnostic kits. The company plans to pursue expansion of its overseas business through this achievement.
GC Green Cross M&S had previously secured export approval for its hantavirus rapid diagnostic kit on October 30. On the 12th, it additionally obtained export approval for a polymerase chain reaction (PCR)-based molecular diagnostic kit. By adding rapid and molecular diagnostic products to its existing ELISA (enzyme-linked immunosorbent assay)-based research diagnostic reagents, the company has expanded its hantavirus diagnostic product lineup.
Rapid diagnostic kits utilize immune responses to provide test results within a short period of time. Molecular diagnostic kits are products that directly detect specific viral genes using PCR technology.
GC Green Cross M&S currently holds approvals for a total of seven infectious disease diagnostic products, including six export-oriented items (four dengue fever diagnostic reagents, one chikungunya diagnostic reagent, and one mpox virus diagnostic reagent) and one domestically marketed malaria diagnostic reagent. With the addition of the hantavirus rapid and molecular diagnostic kits this time, the company has strengthened its infectious disease diagnostic product portfolio.
GC Green Cross M&S plans to continue research and development and commercialization of major infectious disease diagnostic products. The company's strategy is to expand the number of sales countries and product categories for new diagnostic kits by leveraging its existing overseas sales network, thereby broadening its business scope and revenue base in the global infectious disease diagnostic market.
An official from GC Green Cross M&S stated, "We will continue to conduct research, development, and commercialization of diagnostic products targeting major infectious diseases such as mpox and Ebola. Based on our accumulated overseas sales network, we will expand sales countries and product categories to drive revenue growth in the global diagnostics business."